Literature DB >> 18045192

Valproic acid as anti-cancer drug.

Martin Michaelis1, Hans Wilhelm Doerr, Jindrich Cinatl.   

Abstract

The short chain fatty acid valproic acid (VPA, 2-propylpetanoic acid) is approved for the treatment of epilepsia, bipolar disorders and migraine and clinically used for schizophrenia. In 1999, the first clinical anti-cancer trial using VPA was initiated. Currently, VPA is examined in numerous clinical trials for different leukaemias and solid tumour entities. In addition to clinical assessment, the experimental examination of VPA as anti-cancer drug is ongoing and many questions remain unanswered. Although other mechanisms may also contribute to VPA-induced anti-cancer effects, inhibition of histone deacetylases appears to play a central role. This review focuses on recent developments regarding the anti-cancer activity of VPA.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 18045192

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN： 1381-6128            Impact factor:   3.116


  33 in total

1.  Population pharmacokinetics of valproic acid in pediatric patients with epilepsy: considerations for dosing spinal muscular atrophy patients.

Authors:  Jason H Williams; Bhuvaneswari Jayaraman; Kathryn J Swoboda; Jeffrey S Barrett
Journal:  J Clin Pharmacol       Date:  2011-12-13       Impact factor: 3.126

2.  A phase II trial of valproic acid in patients with advanced, radioiodine-resistant thyroid cancers of follicular cell origin.

Authors:  Naris Nilubol; Roxanne Merkel; Lily Yang; Dhaval Patel; James C Reynolds; Samira M Sadowski; Vladimir Neychev; Electron Kebebew
Journal:  Clin Endocrinol (Oxf)       Date:  2016-09-08       Impact factor: 3.478

Review 3.  Treatment of epileptic seizures in brain tumors: a critical review.

Authors:  R Bauer; M Ortler; M Seiz-Rosenhagen; R Maier; J V Anton; I Unterberger
Journal:  Neurosurg Rev       Date:  2014-04-24       Impact factor: 3.042

4.  HDAC inhibitors enhance the lethality of low dose salinomycin in parental and stem-like GBM cells.

Authors:  Laurence Booth; Jane L Roberts; Adam Conley; Nichola Cruickshanks; Thomas Ridder; Steven Grant; Andrew Poklepovic; Paul Dent
Journal:  Cancer Biol Ther       Date:  2013-12-18       Impact factor: 4.742

Review 5.  Neurodevelopmental Perspectives on Wnt Signaling in Psychiatry.

Authors:  Kimberly A Mulligan; Benjamin N R Cheyette
Journal:  Mol Neuropsychiatry       Date:  2017-01-13

6.  Pazopanib and HDAC inhibitors interact to kill sarcoma cells.

Authors:  Seyedmehrad Tavallai; Hossein A Hamed; Steven Grant; Andrew Poklepovic; Paul Dent
Journal:  Cancer Biol Ther       Date:  2014-02-20       Impact factor: 4.742

7.  Cell type-specific anti-cancer properties of valproic acid: independent effects on HDAC activity and Erk1/2 phosphorylation.

Authors:  Kamil Gotfryd; Galina Skladchikova; Eugene A Lepekhin; Vladimir Berezin; Elisabeth Bock; Peter S Walmod
Journal:  BMC Cancer       Date:  2010-07-21       Impact factor: 4.430

8.  Histone deacetylase inhibitors valproate and trichostatin A are toxic to neuroblastoma cells and modulate cytochrome P450 1A1, 1B1 and 3A4 expression in these cells.

Authors:  Jana Hřebačková; Jitka Poljaková; Tomáš Eckschlager; Jan Hraběta; Pavel Procházka; Svatopluk Smutný; Marie Stiborová
Journal:  Interdiscip Toxicol       Date:  2009-09-28

9.  DNA and histone deacetylases as targets for neuroblastoma treatment.

Authors:  Marie Stiborová; Jitka Poljaková; Tomáš Eckschlager; Rene Kizek; Eva Frei
Journal:  Interdiscip Toxicol       Date:  2010-06

10.  Sonoporation-enhanced chemotherapy significantly reduces primary tumour burden in an orthotopic pancreatic cancer xenograft.

Authors:  Spiros Kotopoulis; Anthony Delalande; Mihaela Popa; Veronika Mamaeva; Georg Dimcevski; Odd Helge Gilja; Michiel Postema; Bjørn Tore Gjertsen; Emmet McCormack
Journal:  Mol Imaging Biol       Date:  2014-02       Impact factor: 3.488
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.